文献速递慢性静脉疾病

氰基丙烯酸酯栓塞与静脉腔内激光消融治疗大隐静脉功能不全的系统综述与Meta分析

Cyanoacrylate Embolization versus Endovenous Laser Ablation in Treating Saphenous Vein Insufficiency: A Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2021-11-12

本系统综述与Meta分析纳入5项研究共1432例静脉消融操作(氰基丙烯酸酯栓塞710例、静脉腔内激光消融722例),比较两种方法治疗大隐静脉功能不全的疗效与安全性。结果显示两组静脉闭合率与静脉临床严重程度评分无显著差异,但氰基丙烯酸酯栓塞组围术期疼痛评分更低、皮肤色素沉着率更低(0.60% vs 4.46%)、神经损伤率更低(0% vs 3.94%),且干预时间更快,静脉炎、深静脉血栓和瘀斑发生率无显著差异。

要点

  • 氰基丙烯酸酯栓塞与静脉腔内激光消融的1年静脉闭合率和静脉临床严重程度评分无显著差异。
  • 氰基丙烯酸酯栓塞组围术期疼痛评分更低(P < 0.001)。
  • 氰基丙烯酸酯栓塞组皮肤色素沉着率0.60% vs 静脉腔内激光消融组4.46%(P = 0.008),神经损伤率0% vs 3.94%(P = 0.007)。

核心结论

  • 氰基丙烯酸酯栓塞与静脉腔内激光消融疗效相似,但氰基丙烯酸酯栓塞围术期疼痛更少、皮肤色素沉着和神经损伤发生率更低、干预时间更快。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA声明,检索PubMed、ScienceDirect和Cochrane数据库并手工检索参考文献。
  • 纳入5项研究(2项随机对照试验和3项队列研究),共1432例静脉消融操作(氰基丙烯酸酯栓塞710例,静脉腔内激光消融722例)。
  • 由2名评价者进行数据提取和质量评价,使用RevMan 5.4.0软件进行统计分析。

主要发现

  • 氰基丙烯酸酯栓塞组与静脉腔内激光消融组的静脉闭合率和静脉临床严重程度评分无显著差异。
  • 氰基丙烯酸酯栓塞组围术期疼痛评分低于静脉腔内激光消融组(P < 0.001)。
  • 氰基丙烯酸酯栓塞组皮肤色素沉着率0.60% vs 静脉腔内激光消融组4.46%(P = 0.008)。
  • 氰基丙烯酸酯栓塞组神经损伤率0% vs 静脉腔内激光消融组3.94%(P = 0.007)。
  • 静脉炎、深静脉血栓和瘀斑发生率两组无显著差异;氰基丙烯酸酯栓塞组干预时间显著快于静脉腔内激光消融组(P < 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cyanoacrylate embolization (CAE) is a novel non-thermal non-tumescent venous ablation technique that has shown promising results in treating saphenous vein insufficiency. We aimed to assess the efficacy and safety profile of CAE in comparison to endovenous laser ablation (EVLA) in treating saphenous vein insufficiency. MATERIAL AND METHODS: We conducted a systematic review and meta-analysis in accordance with the PRISMA Statement. A systematic search was performed through online databases including PubMed, ScienceDirect, and Cochrane to find relevant studies. Manual searching was also performed from the references of the selected studies. Specific keywords that we used were "(cyanoacrylate) AND (laser OR laser ablation OR laser therapy) AND (vein OR venous OR saphenous vein OR venous insufficiency OR varicose vein)". Outcomes of interest were efficacy, safety, and intervention time. Efficacy was determined by venous closure rate 1 year post-intervention and Venous Clinical Severity Score (VCSS) 1 year post-intervention. Safety was determined by rates of periprocedural pain, skin pigmentation, nerve damage, phlebitis, deep vein thrombosis (DVT) and ecchymosis. Data extraction and quality assessment of included studies were performed by 2 reviewers, and statistical analysis was conducted using RevMan 5.4.0 software. RESULTS: Five relevant articles (2 randomized-controlled trials and 3 cohort studies) were selected for this study, consisting a total of 1432 venous ablation procedures (710 CAE and 722 EVLA). From the efficacy point of view, venous closure rates and VCSS did not differ significantly between CAE group and EVLA group. From the safety point of view, pooled data showed that CAE group was associated with less periprocedural pain score (P < 0.001), lower skin pigmentation rates (0.60% vs. 4.46%; P = 0.008), and lower nerve damage rates (0% vs. 3.94%; P = 0.007). Rates of phlebitis, deep vein thrombosis, and ecchymosis did not differ significantly between the 2 groups. In addition, intervention time was significantly faster in CAE group compared to EVLA group (P < 0.001). CONCLUSION: Cyanoacrylate embolization yields similar efficacy compared to EVLA. However, CAE is associated with less periprocedural pain, lower occurrence rates of skin pigmentation and nerve damage, and faster intervention time.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Amshar M, Nugraha RA, Batubara EAD, et al. Cyanoacrylate Embolization versus Endovenous Laser Ablation in Treating Saphenous Vein Insufficiency: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2021. PMID: 34780939. doi:10.1016/j.avsg.2021.09.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。